metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | ||||||
mNSCLC - L2 - all population | mNSCLC - L2 - EGFR mutant | mNSCLC - L2 - PDL1 negative | mNSCLC - L2 - PDL1 positive | non squamous - mNSCLC - L2 - all population | squamous - mNSCLC - L2 - all population | |
immune chekpoint inhibitors | ||||||
anti-PD-(L)1 | ||||||
atezolizumab based treatment | ||||||
atezolizumab alone | OAK ... POPLAR | OAK ... | ||||
avelumab based treatment | ||||||
avelumab alone | JAVELIN Lung 200 ... | JAVELIN Lung 200 ... | ||||
durvalumab based treatment | ||||||
durvalumab alone | ARCTIC ... | |||||
durvalumab plus osimertinib | CAURAL ... | |||||
nivolumab based treatment | ||||||
nivolumab alone | CheckMate 078 | CheckMate 057 | CheckMate 017 | |||
pembrolizumab based treatment | ||||||
pembrolizumab alone | ||||||
pembrolizumab (10mg/kg) | KEYNOTE-010 ... KEYNOTE-010 ... | |||||
pembrolizumab (2mg/kg) | KEYNOTE-010 ... KEYNOTE-010 ... | |||||
Tislelizumab | RATIONALE 303 | |||||
Immune checkpoint association | ||||||
durvalumab plus tremelimumab | ARCTIC ... |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-